Endothelin-1 and serotonin: Mediators of primary and secondary pulmonary hypertension?

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 2, 1999, Pages 105-114

  Maclean, Margaret R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033180146     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90114-2     Document Type: Article

References (133)

1. 1. Voelkel NK, Weir EK. Etiologic mechanisms in primary pulmonary hypertension. In: Weir EK, Reeves JT, editors. Pulmonary vascular physiology and pathophysiology. New York: Marcel Dekker; 1989. p. 513-39.
2. 2. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;18:533-47.
3. 3. Haselton PC, Heath D, Brewer DB, Hypertensive pulmonary vascular disease in states of chronic hypoxia. J Pathol Bacteriol 1968;95:431-40.
4. 4. Heath D. The pathology of human pulmonary hypertension. Eur Respir Rev 1993;3:555-8.
5. 5. Heath D, Smith P, Gosney J, Mulcahy D, Fox K, Yacoub M, et al. The pathology of the early and late stages of primary pulmonary hypertension. Br Heart J 1987;58:204-13.
6. 6. McCulloch KM, Docherty CC, MacLean MR. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. Br J Pharmacol 1998;123:1621-30.
7. 7. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 1996;119:917-30.
8. 8. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci 1989;86:2863-7.
9. 9. Yanigasawa M, Kurihara H, Kimura S, Masaki T, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
10. 10. Arai IH, Hori S, Aramori I, Ohkubo H, Nakinishi S, Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:731-2.
11. 11. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, et al. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 1990;348:732-5.
12. 12. Masaki J, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanisms of endothelin regulation. Implications for vascular function. Circulation 1991;84:1457-68.
13. 13. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease. Ann Intern Med 1991;114:464-9.
14. 14. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in pulmonary circulation. Circulation 1991;84:2280-5.
15. 15. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
16. 16. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26:1581-5.
17. 17. Goerre S, Wenk M, Bartsch P, Luscher TF, Niroomand F, Hohenhaus E, et al. Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation 1995;91:359-64.
18. 18. Langleben D, DeMarchie M, Laporta D, Spanier AH, Schlesinger RD, Stewart DJ. Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. Am Rev Respir Dis 1993;148:1646-50.
19. 19. Druml W, Steltzer H, Waldhausl W, Lenz K, Hammerle A, Vierhapper H, et al. Endothelin-1 in adult respiratory distress syndrome. Am Rev Respir Dis 1993;148:1169-73.
20. 20. Yamakami T, Taguchi O, Gabazza EC, Yoshida M, Kobayashi T, Kobayashi H, et al. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise. Eur Respir J 1997;10:2055-60.
21. 21. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-44.
22. 22. Yamamoto K, Ikeda U, Mito H, Fujikawa H, Sekiguchi H, Shimada K. Endothelin production in pulmonary circulation of patients with mitral stenosis. Circulation 1994;89:2093-8.
23. 23. Hemsén A. Biochemical and functional characterisation of endothelin peptides with special reference to vascular effects. Acta Physiol Scand 1991;58:204-13.
24. 24. Firth JD, Radcliffe PJ. Organ distribution of three rat endothelin messenger RNAs and the effect of ischemia on renal gene expression. J Clin Invest 1992;90:1023-31.
25. 25. Marciniak SJ, Plumpton C. Barker PJ, Huskison NS, Davenport AP. Localisation of immunoreactive endothelin and preendothelin in the human lung. Pulm Pharmacol 1992;5:175-82.
26. 26. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
27. 27. Saleh D, Furukawa K, Tsao MS, Maghazachi A, Corrin B, Yanagisawa M, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187-93.
28. 28. Cacoub P, Dorent R, Maistre G, Nataf P, Carayon A, Piette C, et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 1993;71:448-50.
29. 29. Cacoub P, Dorent R, Nataf P, Carayon A, Riquet M, Noc E, et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 1997;33:196-200.
30. 30. McCulloch KM, Docherty CC, Morecroft I, MacLean MR. Endothelin B receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol 1996;119:1125-30.
31. 31. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
32. 32. Sutsch G, Bertel O, Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 1997;10:717-25.
33. 33. Sakai S, Miyauch T, Sakurai T, Yamaguchi T, Kobayashi M, Goto K, et al. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. J Am Coll Cardiol 1996;28:1580-8.
34. 34. Borgeson DD, Grantham JA, Williamson EE, Luschner A, Redfield MM, Opgenorth TJ, et al. Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension 1998;31:766-70.
35. 35. Dupais J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996;94:1578-84.
36. 36. Dupuis J, Goresky CA, Fournier A, Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996;81:1510-5.
37. 37. Kobayshi T, Miyauchi T, Sakai S, Maeda S, Yamaguchi I, Goto K, et al. Down regulation of ET[B) receptor, but not E (A) receptor in congestive lung secondary 10 heart failure. Are marked increases in circulating endothelin-1 partly attributable to decreases in lung ET(B) receptor-mediated clearance of endothelin-1? Life Sci 1998;62:185-93.
38. 38. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994;23:1427-33.
39. 39. Pacher R, Stanek B, Hulmann M, Koller-Strametz J, Berger R, Schuller M, et al. Prognostic impact of big-ET-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-41.
40. 40. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573-9.
41. 41. Ryan US, Glassberg MK, Nolop KB. Endothelin-1 from pulmonary artery and microvessels acts on vascular and airway smooth muscle. Cardiovasc Pharmacol 1989;13(suppl 5):S57-62.
42. 42. Maggi CA, Giuliani S, Patacchini R, Rovero P, Giachetti A, Meli A. The activity of peptides of the endothelin family in various mammalian smooth muscle preparations. Eur J Pharmacol 1989;174:23-31.
43. 43. Lippton HL, Hauth TA, Summer WR, Hyman AL. Endothelin produces pulmonary vasoconstriction and systemic vasodilation. J Appl Physiol 1989;66:1008-12.
44. 44. Braquet P, Touvay C, Lagente V, Vilain B, Pons F, Hosford D, et al. Effect of endothelin-1 on blood pressure and bronchopulmonary system of the guinea pig. J Cardiovasc Pharmacol 1989;13(suppl 5):S143-6.
45. 45. Fukuroda T, Kobayashi M, Ozaki S, Yano M, Miyauchi T, Onizuka M, et al. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol 1994;76:1976-82.
46. 46. Sato K, Oka M, Hasunuma K, Ohnishi M, Sato K, Kira S. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 1995;269:L668-72.
47. 47. MacLean MR, McCulloch KM, Baird M. Endothelin ETA-and ETB-mediated vasoconstriction in rat arteries and arterioles. J Cardiovasc Pharmacol 1994;23:838-45.
48. 48. Hay DWP, Luttmann MA, Pulen MA, Nambi P. Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel ETB receptor subtype. J Pharmacol Exp Ther 1998;284:669-77.
49. 49. Hay DWP, Luttman MA, Beck G, Ohlstein EH. Comparison of endothelin B (ETB) receptors in rabbit isolated pulmonary artery and bronchus. Br J Pharmacol 1996;118:1209-17.
50. 50. Docherty CC, MacLean MR. Endothelin B receptors in rabbit pulmonary resistance arteries: effect of left ventricular dysfunction. J Pharmacol Exp Ther 1998;284:895-903.
51. 51. MacLean MR, McCulloch KM, Baird M. Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6c, and on inherent tone in rat pulmonary arteries. J Cardiovasc Pharmacol 1995;26:822-30.
52. 52. Bialecki RA, Fisher CS, Murdoch WW, Barthlow HG, Bertelsen DL. Functional comparison of endothelin receptors in human and rat pulmonary artery smooth muscle. Am J Physiol 1997;272:L211-8.
53. 53. Li H, Chen S, Chen Y, Meng QC, Durand J, Oparil S, et al. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol 1994;77:1451-9.
54. 54. Li H, Elton TS, Chen F, Oparil S. Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol 1994;266:L553-60.
55. 55. Elton TS, Oparil S, Taylor GR, Hicks PH, Yang R, Jin H, et al. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am J Physiol 1992;263:R1260-4.
56. 56. Yorikane R, Miyauchi T, Sakai S, Sakurai T, Yamaguchi I, Sugishita Y, et al. Altered expression of ETB-receptor mRNA in the lung of rats with pulmonary hypertension. J Cardiovasc Physiol 1993;22(suppl 8):S336-8.
57. 57. DiCarlo VS, Chen S-J, Meng QC, Durand J, Yano M, Chen Y-F, et al. ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in the rat. Am J Physiol 1995;269:L690-7.
58. 58. Bonvallet ST, Zamora MR, Hasunuma K, Sato K, Hanasato N, Anderson D, et al. BQ123, an ETA-rcceptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1994;266:H1327-31.
59. 59. Chen S-J, Chen Y-F, Opgenorth TJ, Wessale JL, Meng QC, Durand J, et al. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodelling in Sprague-Dawley rats. J Cardiovasc Pharmacol 1997;29:713-25.
60. 60. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S. Protection from pulmonary hypertension with an orally active endothelin antagonist in hypoxic rats. Am J Physiol 1995;268:H828-35.
61. 61. Chen S-J, Chen Y-F, Meng QC, Durand J, DiCarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31.
62. 62. Underwood DC, Bochnowicz S, Osborn RR, Louden CS, Hart TK, Ohlstein EH, et al. Chronic hypoxia-induced cardiopulmonary changes in three rat strains: inhibition by the ET receptor antagonist, SB 217242. J Cardiovasc Pharmacol 1998;31(suppl 1):S453-5.
63. A-receptor antagonist, in chronic heart failure. Lancet 1998;352:201-2.
64. 64. Lal H, Woodward B, Williams KI. Investigations of the contributions of nitric oxide and prostaglandins to the actions of endothelins and sarafotoxin 6c in rat isolated perfused lungs. Br J Pharmacol 1996;118:1931-8.
65. 65. Ahlborg G, Ottosson-Seeberger A, Hemsen A, Lundberg JM. Central and regional hemodynamic effects during infusion of big endothelin-1 in healthy humans. J Appl Physiol 1996;80:1921-7.
66. 66. Kiely DG, Cargill RI, Struthers AD, Lipworth BJ. Cardiopulmonary effects of endothelin-1 in man. Cardiovasc Res 1997;33:378-86.
67. 67. Cowburn PJ, Cleland JGF, McArthur JD, MacLean MR, Dargie HJ, McMurray JJV, et al. Pulmonary and systemic responses to exogenous ET-1 in patients with left ventricular dysfunction. Cardiovasc Res 1998;39:563-70.
68. 68. Deuchar GA, Hicks MN, Cobbe SM, Docherty CC, MacLean MR. Pulmonary responses to 5-hydroxytryptamine and endothelin-1 in a rabbit model of left ventricular dysfunction. Cardiovasc Res 1998;38:500-7.
69. 69. MacLean MR, Deuchar G, Hicks M, Cobbe S. Pulmonary arterial endothelial release of nitric oxide protects against circulating endothelin-1 in a rabbit model of pulmonary hypertension secondary to left ventricular dysfunction. Am J Respir Crit Care Med. 1999;105:334.
70. 70. Holm P, Franco-Cereceda A. Tissue concentrations of endothelins and functional effects of endothelin-receptor activation in human arteries and veins. J Thorac Cardiovasc Surg 1996;112:264-72.
71. 71. Janakidevi K, Fisher MA, Del Vecchio PJ, Tiruppathi C, Figge J, Malik AB. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 1992;263:C1295-301.
72. 72. Feng X, Cai Y. Hypoxia and endothelin-1 stimulate DNA synthesis of pulmonary artery smooth muscle cells. China Med Sci J 1996;11:28-31.
73. 73. Zamora MA, Stelzner TJ, Webb S, Panos RJ, Ruff LJ, Demsey EC. Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats. Am J Physiol 1996;270:L101-9.
74. A receptor antagonist, inhibits endothelin1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 1993;9:429-33.
75. 75. Chen Y, Sun Y, Lin J, Zhou A, Wang H. Research on the mechanism of endothelin inflammatory effects on human mesengial cells. Chin Med J (Engl) 1997;110:530-4.
76. 76. Finsnes F, Christensen G, Lyberg T, Sejersted OM, Skjonsberg OH. Increased synthesis and release of endothelin-1 during the initial phase of airway inflammation. Am J Respir Crit Care Med 1998;158:1600-6.
77. 77. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med 1998;132:16-24.
78. 78. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-16.
79. 79. Seiler KU, Wasserman O. MAO-inhibitory properties of anorectic drugs. J Pharm Pharmacol 1973;25:576-8.
80. 80. Seiler KU, Wassermann O, Wensky H. On the role of serotonin in the pathogenesis of pulmonary hypertension induced by anorectic drugs: an experimental study in the isolated perfused rat lung. II. Fenfluramine, mazindol, mefenorex, phentermine and R 800. Clin Exp Pharmacol Physiol 1976;3:323-40.
81. 81. Voelkel NF. Appetite suppressants and pulmonary hypertension. Thorax 1997;52(suppl 3):S63-7.
82. 82. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into brain synaptosomes and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984;104:277-86.
83. 83. Cheetham SC, Viggers JA, Slater NA, Heal DJ, Buckett WR. [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments. Neuropharmacol 1993;32:737-43.
84. 84. Bolden-Watson C, Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-9.
85. 85. Heal DJ, Cheetham SC, Prow MR, Martin KF, Buckett WR. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 1998;125:301-8.
86. 86. Lancashire B, Viggers J, Prow MR, Aspley S, Martin KF, Cheetham SC, et al. Monoamine release and uptake inhibition profiles of antiobesity agents. J Psychopharmacol 1998;12(suppl):A143P.
87. 87. Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick G. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol Pharmacol 1993;44:1227-31.
88. 88. Rudnick G, Wall SC. Non-neurotxic amphetamine derivatives release serotonin through srotonin transporters. Mol Pharmacol 1993;43:271-6.
89. 89. Picotti GB, Carruba MO, Zambotti F, Mantegazza P. Effect of mazindol and D-fenfluramine of 5-hydroxytryptamine uptake, storage and metabolism in blood platelets. Eur J Pharmacol 1977;42:217-24.
90. 90. Buczko W, De Gaetano G, Garattini S. Effect of fenfluramine on 5-hydroxytryptamine uptake and release by rat blood platelets. Br J Pharmacol 1975;53:563-8.
91. 91. Fristrom S, Airaksinen MM, Halmekoski J. Release of platelet 5-hydroxytryptamine by some anorexic and other sympathomimetics and their acetyl derivatives. Acta Pharmacol Toxicol (Copenh) 1977;41:218-24.
92. 92. Schaiberger PH, Kennedy TC, Miller FC, Gal J, Petty TL. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 1993;104:614-6.
93. 93. McMurray J, Bloomfield P, Miller HC. Irreversible pulmonary hypertension after treatment with fenfluramine. Br Med J 1986;292:239-40.
94. 94. Gurtner HP. Aminorex and pulmonary hypertension. Cor Vasa 1985;27:160-71.
95. 95. Backmann R, Dengler H, Gahl K, Greiser E, Jesdinsky HJ, Loogen F. Primary pulmonary hypertension. Report from the Commission of the German Society for Circulatory Research. Darmstadt: Dr Dietrich Steinkopff Publishers; 1972. p. 134-41.
96. 96. Osipenko ON, Alexander D, MacLean MR, Gurney AM. Influence of chronic hypoxia on the contributions of on-inactivating and delayed K current to the resting potential and tone of rat pulmonary artery smooth muscle cells. Br J Pharmacol 1998;124:1335-7.
97. 97. Weir EK, Archer SL. The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels. FASEB J 1995;9:183-9.
98. 98. Michelakis ED, Reeve HL, Huang JM, Tolarova S, Nelson DP, Weir EK, et al. Potassium channel diversity in vascular smooth muscle cells. Can J Physiol Pharmacol 1997;75:889-97.
99. + current in rat pulmonary arterial cells. Am J Physiol 1994;266:H365-70.
100. 100. Wang J, Juhaszova M, Rubin LJ, Yuan XJ. Hypoxia inhibits gene expression of voltage-gated K channel α-sub-units in pulmonary artery smooth muscle cells. J Clin Invest 1997;100:2347-53.
101. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998;98:1400-6.
102. 102. Weir EK, Reeve HL, Johnson G, Michelakis ED, Nelson DP, Archer SL, A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension. Chest 1998;114:200-4S.
103. 103. Reeve HL, Nelson DP, Archer SL, Weir EK. Effects of fluoxetine, phentermine and venlafxine on pulmonary arterial pressure and electrophysiology. Am J Physiol 1999;276:L213-9.
104. 104. Johnson DE, Georgieff MK. Pulmonary neuroendocrine cells. Their secretory products and their potential roles in health and chronic lung disease in infancy. Am Rev Respir Dis 1989;140:1807-12.
105. 105. Gould VE, Linnoila RI, Memoli VA, Warren WH. Neuroendocrine components of the bronchpulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest 1983;49:519-37.
106. 106. Hervé P, Launay J-M, Scrobohaci M-L, Brenot F, Simonneau G, Petitpretz P, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-54.
107. 107. Klimiuk PS, Grennan A, Weinkove C, Jayson MIV. Platelet serotonin in systemic sclerosis. Ann Rheum Dis 1989;48:586-9.
108. 108. Brenot F, Hervé P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1995;70:537-41.
109. 109. Maher TJ, Ulus IH, Wurtman RJ. Phentermine and other monomine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines. The Lancet 1999;353:38.
110. 110. Hervé P, Drouet L, Dosquet C, Launay J-M, Rain B, Simonneau G, et al. Primary pulmonary hypertension in a patient with familial storage pool disease: role of serotonin. Am J Med 1990;89:117-20.
111. 111. Gonzalez AM, Smith AP, Emery CJ, Higenbottam TW. The pulmonary hypertensive fawn-hooded rat has a normal serotonin transporter coding sequence. Am J Respir Cell Mol Biol 1998;19:245-9.
112. 112. Linden AS, Desmecht DJ, Amory H, Beduin JM, Lekeux PM. Cardiovascular responses to exogenous serotonin in healthy calves. Am J Vet Res 1996;57:731-8.
113. 113. al-Tinawi A, Krenz GS, Rickaby DA, Linehan JH, Dawson CA. Influence of hypoxia and serotonin on small pulmonary vessels. J Appl Physiol 1994;76:56-64.
114. 114. Eddahibi S, Raffestin B, Pham I, Launay JM, Aegerter P, Sitbon M, et al. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol 1997;272:H1173-81.
115. 115. Brink C, Cerrina C, Labat C, Verley J, Beneveniste J. The effect of contractile agonists on isolated pulmonary arterial and venous muscle preparations derived from patients with primary pulmonary hypertension. Am Rev Respir Dis 1988;137:A106.
116. 116. Domenighetti G, Leuenberger P, Feihl F. Haemodynamic effects of ketanserin either alone or with oxygen in COPD patients with secondary pulmonary hypertension. Monaldi Arch Chest Dis 1997;52:429-33.
117. 117. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203.
118. 118. Arnekdo-Nobin B, Nobin A, Owman C, Tornebrandt K. Serotonergic mechanisms in isolated human peripheral arteries and veins. J Cardiovasc Pharmacol 1985;7(suppl 7):S52-5.
119. 119. McIntyre PE, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 1992;34:541-6.
120. 1-like receptor mediated vasoconstriction in human pulmonary artery. Br J Pharmacol 1996;119:277-82.
121. 1B receptor. Br J Pharmacol. In press.
122. 122. Anderson GM, Stevenson JM, Cohen DJ. Steady-state model for plasma free and platelet serotonin in man. Life Sci 1987;41:1777-85.
123. 123. Leff P. An analysis of amplifying and potentiating interactions between agonists. J Pharmacol Exp Ther 1987;243:1035-42.
124. 1-receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influence of vascular endothelium and tone. Pulm Pharmacol 1994;7:65-72.
125. 125. Sweency G, Templeton A, Clayton RA, Baird M, Sheridan S, Johnston ED, et al. Contractile responses to sumatriptan in isolated bovine pulmonary artery rings: relationship to tone and cyclic nucleotide levels. J Cardiovasc Pharmacol 1995;26:751-60.
126. 126. MacLean MR, Smith GC, Templeton AGB. Adverse reactions to sumatriptan [letter]. Lancet 1993;341:1092, 1164.
127. 127. MacLean MR, Johnston ED, McCulluch KM, Pooley L, Houslay M, Sweeney G. Phosphodicsterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997;283:619-24.
128. 128. Fanburg BL, Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 1997;272:L795-806.
129. 129. Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994;266:L46-52.
130. 130. Lee SL, Wang WW, Fanburg BL. Superoxide as an intermediate signal for serotonin-induced mitogenesis. Free Radic Biol Med 1998;24:855-8.
131. 131. Lee SL, Wang WW, Fanburg BL. Association of Tyr phosphorylation of GTPase-activating protein with mitogenic action of serotonin. Am J Physiol 1997;272:C223-30.
132. 132. Eddahibi S, Fahre V, Boni C, Martres MP, Raffestin B, Hamon M, et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells: relationship with the mitogenic action of serotonin. Circ Res. In press.
133. 133. MacLean MR. Endothelin-1: a mediator of pulmonary hypertension? Pulm Pharmacol Ther 1998;11:125-32.